Activated d16HER2 homodimers and src kinase mediate optimal efficacy for trastuzumab

Cancer Research

Volumn 74, Issue 21, 2014, Pages 6248-6259

  Castagnoli, Lorenzo ^a   Iezzi, Manuela ^b   Ghedini, Gaia C ^a   Ciravolo, Valentina ^a   Marzano, Giulia ^a   Lamolinara, Alessia ^b   Zappasodi, Roberta ^c   Gasparini, Patrizia ^d   Campiglio, Manuela ^a   Amici, Augusto ^e   Chiodoni, Claudia ^a   Palladini, Arianna ^f   Lollini, Pier Luigi ^f   Triulzi, Tiziana ^a   Menard, Sylvie ^a   Nanni, Patrizia ^f   Tagliabue, Elda ^a   Pupa, Serenella M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c C Gandini Medical Oncology Bone Marrow Transplantation Unit Department of Experimental Oncology and Molecular Medicine   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF CAMERINO   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROITEN D16HER2; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; ISOPROTEIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARCINOGENICITY; CONTROLLED STUDY; D16HER2 GENE; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WTHER2 GENE; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; EXON; GENETICS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROTEIN MULTIMERIZATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84909609669     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0983     Document Type: Article

References (41)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32.
3. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 2011;22:1308-17.
4. Tagliabue E, Campiglio M, Pupa SM,Menard S, Balsari A. Activity and resistance mechanisms of trastuzumab in different clinical settings. Cancer Treat Rev 2012;38:212-7.
5. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38.
6. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramon C, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009;29:3319-31.
7. Bose R, KavuriSM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-37.
8. Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998;23:62-8.
9. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A,Menard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer 2006;13:221-32.
10. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009;8:2152-62.
11. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15.
12. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
13. Bargmann CI, Weinberg RA. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988;7: 2043-52.
14. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the mmtv/c-neu oncogene. Cell 1989;57:931-6.
15. Suda Y, Aizawa S, Furuta Y, Yagi T, Ikawa Y, Saitoh K, et al. Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659-Glu659). EMBO J 1990;9:181-90.
16. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171:5787-94.
17. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004;10:2499-511.
18. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389-97.
19. Marchini C, Gabrielli F, Iezzi M, Zanobi S, Montani M, Pietrella L, et al. The human splice variant delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS ONE 2011;6:e18727.
20. Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, et al. Mammary tumor formation and metastasis evoked by a HER2 splice variant. Cancer Res 2013;73:5320-7.
21. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin Cancer Res 2009;15:2010-21.
22. Ghedini GC, Ciravolo V, Tortoreto M, Giuffre S, Bianchi F, Campiglio M, et al. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol 2010;225: 256-65.
23. Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, et al. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 2008;27:7150-61.
24. Triulzi T, Casalini P, Sandri M, Ratti F, Carcangiu ML, Colombo MP, et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS ONE 2013;8:e56761.
25. Cox DR. Regression models and life tables. J R Stat Soc 1972;34: 187-220.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
27. Gluck S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine / trastuzumab. Breast Cancer Res Treat 2012;132:781-91.
28. de Ronde JJ, Rigaill G, Rottenberg S, Rodenhuis S, Wessels LF. Identifying subgroup markers in heterogeneous populations. Nucleic Acids Res 2013;41:e200.
29. Hajian-Tilaki KO, Hanley JA, Joseph L, Collet JP. A comparison of parametric and nonparametric approaches to ROC analysis of quantitative diagnostic tests. Med Decis Making 1997;17:94-102.
30. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealingwith the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47.
31. Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D, et al. Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene 2014;33:619-31.
32. Jackson C, Browell D, Gautrey H, Tyson-Capper A. Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int J Cell Biol 2013;2013:973584.
33. Zagozdzon R, Gallagher WM, Crown J. Truncated HER2: implications for HER2-targeted therapeutics. Drug Discov Today 2011;16: 810-6.
34. Krop IE, Burstein HJ. Trastuzumab: qui bono? J Natl Cancer Inst 2013;105:1772-5.
35. Pupa SM, Campiglio M, Rossini A, Orlandi R, Ciravolo V, Amici A, et al., Role of D16HER2 splice variant in breast tumor progression and response to HER2-targeted therapy. In: Williams SI, Rogers CE, editors. HER2 and Cancer: Mechanism, Testing and Targeted Therapy. Hauppauge, NY: Nova Science Publishers, Inc. 2011. p. 201-9.
36. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011;11:793-800.
37. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012;17:1-16.
38. Ghosh R, Narasanna A, WangSE, Liu S, Chakrabarty A, Balko JM, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 2011;71:1871-82.
39. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223:14-26.
40. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17:461-9.
41. Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, et al. Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat 2013;141:101-10.